奇米中文字幕在线观看_尤物yw193在线视频_午夜欧美精品久久久国产片_欧美一级a爱做片观看免费_亞洲AV無碼片VR一區二區三區_国产麻豆精品一精品_男女猛烈无遮挡午夜视频网站_成全视频在线观看中文版

Why collaborate with us?
  • 研究領(lǐng)域.svg
    Research Focus
    We specialize in CAR-T cell therapy and have established multiple pioneering platforms, including rapid autologous CAR-T manufacturing platform, allogeneic CAR-T platform, and in vivo?engineered CAR-T platform. These innovations significantly reduce the production cost of cell-based therapeutic products.
  • Pipeline Portfolio
    Our differentiated candidate products targeting a wide range of indications, including hematological malignancies, solid tumors, and autoimmune diseases. Multiple candidates have already entered clinical trial stages.
  • 全流程CAR.svg
    CAR-T Manufacturing Capacity
    We have the capability from antibody screening，CAR design，lentivirus packaging to CAR-T manufacture and quality control.
  • 管理團(tuán)隊.svg
    Leadership Team
    A visionary management team with rich industry experience and successful entrepreneurial track records.
Collaboration
  • 合作開發(fā).svg
    Guangzhou Bio-gene is developing a pipeline of cell therapy products targeting malignant tumors and autoimmune diseases. We look forward to collaborating with potential partners who plan to expand into these fields and possess differentiated advantages, to jointly develop targeted products and advance them through the commercialization process.
  • 技術(shù)服.svg
    We provide a comprehensive suite of technical services to support CAR-T product pipeline development, including antibody screening, vector design, vector preparation and production, as well as lentivirus packaging and production. We offer customized services for both research-grade and GMP-compliant plasmid vectors and lentiviruses to meet diverse client requirements.
  • 產(chǎn)品授權(quán).svg
    To further unlock the market potential of our innovative therapies, we are open to collaborating with global partners through flexible commercial licensing models. We offer comprehensive or region- and indication-specific licensing options for assets within our pipeline to maximize both clinical and commercial value.